Study S000057

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

ClinicalTrials.gov record

Registration

Registration: NCT06994650
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 140
Start: 2025-08-13
Primary completion: 2026-12
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
Interventions: DRUG:HRS9531; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

The change of AHI form baseline after 52 weeks of treatment [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.